Press Release

United States Retail Pharmacy De-identified Health Data Market to Grow with a CAGR of 7.91% through 2030

The rising adoption of real-time prescription data sharing for care coordination and the expanding role of retail pharmacies in value-based healthcare programs, is expected to drive the United States Retail Pharmacy De-identified Health Data Market growth in the forecast period, 2026-2030

 

According to TechSci Research report, “United States Retail Pharmacy De-identified Health Data Market – By Region, Competition, Forecast & Opportunities, 2030F”, the United States Retail Pharmacy De-identified Health Data Market was valued at USD 2.95 Billion in 2024 and is expected to reach USD 4.66 Billion by 2030 with a CAGR of 7.91%. The United States Retail Pharmacy De-identified Health Data Market is experiencing expansion as healthcare stakeholders increasingly recognize the commercial and clinical value of aggregated, anonymized datasets generated by retail pharmacies. Large pharmacy chains serve as vital access points for patient interactions, generating a continuous flow of data related to prescription dispensing, over-the-counter purchases, and wellness services. When stripped of personal identifiers, this information becomes a valuable resource for pharmaceutical research, formulary optimization, and public health surveillance. The rapid proliferation of electronic prescription systems and point-of-sale health data capture has significantly enhanced the scope and depth of available datasets. Continuous investment by retail pharmacies in digital infrastructure is enabling more efficient extraction, curation, and distribution of de-identified datasets to interested buyers across the healthcare ecosystem.

A notable market trend is the growing use of cloud-based health data exchange platforms that allow authorized stakeholders to securely access large-scale pharmacy datasets. These systems promote real-time data availability, enabling researchers and industry players to track emerging prescription trends, monitor therapeutic adoption rates, and detect early signs of potential health crises. Strategic alliances between pharmacies, academic institutions, and analytics firms are accelerating the application of predictive modeling in areas such as drug safety monitoring and chronic disease management. Enhanced use of blockchain technology is also emerging, ensuring secure, tamper-proof data transactions while maintaining regulatory compliance. The rise in consumer-driven healthcare models is further encouraging the use of aggregated pharmacy data to understand behavior patterns and align service delivery with evolving patient preferences.

Significant growth opportunities lie in expanding the application of de-identified pharmacy datasets into emerging healthcare areas such as pharmacogenomics, real-world evidence generation, and predictive health risk modeling. The increasing adoption of wearable devices and mobile health applications opens pathways for combining pharmacy transaction data with lifestyle and biometric data, creating richer datasets for precision healthcare initiatives. Retail pharmacies can also monetize insights to support payers in designing risk-adjusted insurance models or aid policymakers in shaping targeted health interventions. With growing demand from life sciences companies for real-world data in post-market drug surveillance and therapy optimization, retail pharmacies stand to become critical partners in the next phase of data-driven healthcare innovation in the United States.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Retail Pharmacy De-identified Health Data Market

 

The United States Retail Pharmacy De-identified Health Data Market is segmented into dataset type, regional distribution, and company.

Based on the Dataset Type, Episodic Data/Pharmacy Rx Claims Data emerged as the fastest growing segment in the United States Retail Pharmacy De-identified Health Data Market during the forecast period. This is driven by the rich, detailed insights this data provides regarding patient medication histories, prescription fill patterns, and treatment adherence. Pharmacy Rx Claims Data enables healthcare providers, pharmaceutical companies, and payers to analyze real-world medication usage and outcomes, supporting more informed decision-making in clinical care and drug development. The increasing digitization of pharmacy claims processes, coupled with the widespread adoption of electronic health records and pharmacy management systems, has significantly expanded the volume and quality of episodic data available for analysis. Moreover, the growing emphasis on value-based care and outcomes-driven reimbursement models relies heavily on this data to assess treatment effectiveness and optimize healthcare spending.

Based on the Region, West emerged as the fastest growing region in the United States Retail Pharmacy De-identified Health Data Market during the forecast period. This is driven by a combination of technological advancement and increasing healthcare digitization. States in this region, such as California, Washington, and Oregon, have been at the forefront of adopting advanced data analytics platforms, cloud-based storage solutions, and artificial intelligence for healthcare applications. Strong collaborations between retail pharmacy chains, health tech startups, and research institutions have facilitated the development of more comprehensive and actionable de-identified health datasets. This has enhanced the value proposition of retail pharmacies as key stakeholders in healthcare data ecosystems. The region’s growing emphasis on preventive healthcare and personalized medicine is fueling demand for high-quality, de-identified datasets that can be leveraged for predictive analytics, population health management, and targeted intervention strategies.

  

Major companies operating in United States Retail Pharmacy De-identified Health Data Market are:

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Walmart Inc.
  • The Kroger Co.
  • Albertsons Companies, Inc.
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BrightSpring Health Services, Inc.
  • Costco Wholesale Corporation
  • Centene Corporation

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

The United States Retail Pharmacy De-identified Health Data Market is expanding due to the rising adoption of interoperable health data exchange platforms by retail pharmacies, which is transforming the way pharmacy-generated data is utilized across the healthcare ecosystem. Interoperability enables seamless integration of prescription records, medication adherence information, and other pharmacy-related datasets with electronic health records (EHRs) and clinical decision support systems (CDSS). This interconnected approach allows healthcare providers to access a more complete patient profile, improving diagnosis accuracy, treatment personalization, and care coordination between physicians, pharmacists, and other stakeholders. These factors are expected to drive the market's expansion throughout the forecast period.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

United States Retail Pharmacy De-identified Health Data Market By Dataset Type [DSCSA Data {By Buyer Type (Pharmaceutical Manufacturers, Drug Distributors, Regulatory Tech Vendors, Healthcare SaaS Vendors, Others)}; Market Basket Data {By Buyer Type (CPG & Pharma Brands, Marketing & AdTech Firms, Health Insurers & PBMs, Retail Analytics Platforms, Others)}; Prior Authorization Data {By Buyer Type (Payers & PBMs, Pharma Market Access Teams, Health IT Providers, Consulting & Policy Firms, Others)}; Inventory Data {By Buyer Type (Pharma Manufacturers, Distributors/Wholesalers, AI/ML Inventory Optimization Vendors, Others)}; Episodic Data/Pharmacy Rx Claims Data {By Buyer Type (Value-based Payers & ACOs, Pharma Outcomes Teams, Real-world Evidence Vendors, CMS & Government Organizations, Others)}], By Region and Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of United States Retail Pharmacy De-identified Health Data Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Retail Pharmacy De-identified Health Data Market.

 

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News